Literature DB >> 17695668

A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta.

Ramesh K Selvaraj1, Terrence L Geiger.   

Abstract

TGF-beta induces Foxp3 expression in stimulated T cells. These Foxp3+ cells (induced regulatory T cells (iTreg)) share functional and therapeutic properties with thymic-derived Foxp3+ regulatory T cells (natural regulatory T cells (nTreg)). We performed a single-cell analysis to better characterize the regulation of Foxp3 in iTreg in vitro and assess their dynamics after transfer in vivo. TGF-beta up-regulated Foxp3 in CD4+Foxp3- T cells only when added within a 2- to 3-day window of CD3/CD28 stimulation. Up to 90% conversion occurred, beginning after 1-2 days of treatment. Foxp3 expression strictly required TCR stimulation but not costimulation and was independent of cell cycling. Removal of TGF-beta led to a loss of Foxp3 expression after an approximately 4-day lag. Most iTreg transferred into wild-type mice down-regulated Foxp3 within 2 days, and these Foxp3- cells were concentrated in the blood, spleen, lung, and liver. Few of the Foxp3- cells were detected by 28 days after transfer. However, some Foxp3+ cells persisted even to this late time point, and these preferentially localized to the lymph nodes and bone marrow. CXCR4 was preferentially expressed on Foxp3+ iTreg within the bone marrow, and CD62L was preferentially expressed on those in the lymph nodes. Like transferred nTreg and in contrast with revertant Foxp3- cells, Foxp3+ iTreg retained CD25 and glucocorticoid-induced TNFR family-related gene. Thus, Foxp3 expression in naïve-stimulated T cells is transient in vitro, dependent on TGF-beta activity within a highly restricted window after activation and continuous TGF-beta presence. In vivo, a subset of transferred iTreg persist long term, potentially providing a lasting source for regulatory activity after therapeutic administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17695668

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer.

Authors:  Frances Mercer; Derya Unutmaz
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 2.  Regulatory T-cell stability and plasticity in mucosal and systemic immune systems.

Authors:  M Murai; P Krause; H Cheroutre; M Kronenberg
Journal:  Mucosal Immunol       Date:  2010-05-26       Impact factor: 7.313

3.  Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells.

Authors:  Siddharth Jhunjhunwala; Stephen C Balmert; Giorgio Raimondi; Eefje Dons; Erin E Nichols; Angus W Thomson; Steven R Little
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

4.  Phenotype and function of regulatory T cells in the genital tract.

Authors:  Janina Jiang; Kathleen A Kelly
Journal:  Curr Trends Immunol       Date:  2011

5.  HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.

Authors:  Jun Li; Jessica Heinrichs; Kelley Haarberg; Kenrick Semple; Anandharaman Veerapathran; Chen Liu; Claudio Anasetti; Xue-Zhong Yu
Journal:  J Immunol       Date:  2015-06-05       Impact factor: 5.422

6.  Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.

Authors:  Maura Rossetti; Roberto Spreafico; Suzan Saidin; Camillus Chua; Maryam Moshref; Jing Yao Leong; York Kiat Tan; Julian Thumboo; Jorg van Loosdregt; Salvatore Albani
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

Review 7.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

8.  Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development.

Authors:  Diana Milojevic; Khoa D Nguyen; Diane Wara; Elizabeth D Mellins
Journal:  Pediatr Rheumatol Online J       Date:  2008-12-01       Impact factor: 3.054

9.  HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta.

Authors:  Caroline H T Hall; Rachel Kassel; Robert S Tacke; Young S Hahn
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

10.  Molecular antagonism and plasticity of regulatory and inflammatory T cell programs.

Authors:  Xuexian O Yang; Roza Nurieva; Gustavo J Martinez; Hong Soon Kang; Yeonseok Chung; Bhanu P Pappu; Bhavin Shah; Seon Hee Chang; Kimberly S Schluns; Stephanie S Watowich; Xin-Hua Feng; Anton M Jetten; Chen Dong
Journal:  Immunity       Date:  2008-06-26       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.